Advanced BiomedADVB +3.10%12 Return-on-Tangible-Equity is -20.93% as of Mar. 2026. GuruFocus rates ADVB with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 192 Medical Diagnostics & Research companies, Advanced Biomed ranks better than 85.42% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Advanced Biomed's annualized net income for the quarter that ended in Mar. 2026 was $-1.96 Mil. Advanced Biomed's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $9.35 Mil. Therefore, Advanced Biomed's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -20.93%.
The historical rank and industry rank for Advanced Biomed's Return-on-Tangible-Equity or its related term are showing as below:
ADVB'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -214 Med: -188.22 Max: 90.15
Current: 90.15
During the past 5 years, Advanced Biomed's highest Return-on-Tangible-Equity was 90.15%. The lowest was -214.00%. And the median was -188.22%.
ADVB's Return-on-Tangible-Equity is ranked better than 85.42% of 192
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.405
vs ADVB: 90.15
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Advanced Biomed Return-on-Tangible-Equity Related Terms
Advanced Biomed Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Advanced Biomed's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADVB vs MBAI, XWEL, NDRA: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, Advanced Biomed's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Advanced Biomed Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Advanced Biomed's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Advanced Biomed's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -20.93% mean?
Advanced Biomed (ADVB) has a Return-on-Tangible-Equity of -20.93% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Advanced Biomed and its competitors. According to the industry distribution chart, Advanced Biomed ranks #28 out of 192 companies in the Medical Diagnostics & Research industry, placing it in the top 14.6%.
Is Advanced Biomed's Return-on-Tangible-Equity too high?
Advanced Biomed's current Return-on-Tangible-Equity is -20.93%. Based on the distribution chart, Advanced Biomed ranks #28 out of 192 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Advanced Biomed has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Advanced Biomed's Return-on-Tangible-Equity compare to MBAI and XWEL?
According to the Medical Diagnostics & Research industry distribution chart, Advanced Biomed ranks #28 out of 192 companies for Return-on-Tangible-Equity. This places Advanced Biomed in the top 15% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Equity depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Advanced Biomed and its competitors. Advanced Biomed's current Return-on-Tangible-Equity is -20.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Biomed stock overvalued right now?
Advanced Biomed (ADVB) has a current Return-on-Tangible-Equity of -20.93%. The current Return-on-Tangible-Equity is -20.93%. Advanced Biomed's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Advanced Biomed (ADVB), the current Return-on-Tangible-Equity is -20.93% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.
12GF Score
Get the complete analysis for ADVB
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADVB has been successfully added to your 
